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TBZE-029 {1-(2,6-difluorophenyl)-6-trifluoromethyl-1H,3H-thiazolo[3,4-a]benzimidazole} is a novel selec-
tive inhibitor of the replication of several enteroviruses. We show that TBZE-029 exerts its antiviral activity
through inhibition of viral RNA replication, without affecting polyprotein processing. To identify the viral
target of TBZE-029, drug-resistant coxsackievirus B3 (CVB3) was selected. Genotyping of resistant clones led
to the identification of three amino acid mutations in nonstructural protein 2C, clustered at amino acid
positions 224, 227, and 229, immediately downstream of NTPase/helicase motif C. The mutations were rein-
troduced, either alone or combined, into an infectious full-length CVB3 clone. In particular the mutations at
positions 227 and 229 proved essential for the altered sensitivity of CVB3 to TBZE-029. Resistant virus
exhibited cross-resistance to the earlier-reported antienterovirus agents targeting 2C, namely, guanidine hydro-
chloride, HBB [2-(alpha-hydroxybenzyl)-benzimidazole], and MRL-1237 {1-(4-fluorophenyl)-2-[(4-imino-1,4-dihy-
dropyridin-1-yl)methyl]benzimidazole hydrochloride}. The ATPase activity of 2C, however, remained unaltered
in the presence of TBZE-029.
Entero- and rhinoviruses are involved in a wide range of
infections in humans and animals. Among the species in the
enterovirus genus are the coxsackieviruses, which have been
reported to be associated with various clinical manifestations,
including myocarditis, pancreatitis, meningitis, and encephali-
tis. Other clinically relevant enteroviruses are poliovirus, which
can cause paralytic poliomyelitis, and echovirus, causing asep-
tic meningitis or encephalomyelitis (33, 36, 43). Rhinoviruses
are the main pathogens associated with the common cold, and,
although usually mild and self-limiting, rhinovirus infections
have an enormous socioeconomical impact (47, 59).
Enteroviruses belong to the family Picornaviridae, which
consists of small, nonenveloped viruses containing a single-
stranded positive-strand RNA [()RNA] genome of 7.5 kb,
which is covalently linked to a small viral protein (VPg) at its
5 end and polyadenylated at its 3 end (49). The genomic
RNA has a long, highly structured 5 noncoding region, which
contains the internal ribosome entry site, necessary for trans-
lation initiation, and a shorter 3 noncoding region preceding
the poly(A) tract, which are both thought to be involved in
RNA replication and translation (9). The coding region en-
codes a single polyprotein that will eventually be cleaved to
generate 4 structural and 10 nonstructural proteins (either
mature or in their precursor form). The icosahedral capsid of
the virus is formed by 60 protomers, each one assembled by the
four structural proteins, designated VP1 to -4. The nonstruc-
tural region comprises two proteases, the viral RNA-depen-
dent RNA polymerase and seven other proteins that are in-
volved in viral replication (8).
One of the most conserved nonstructural viral proteins
among picornaviruses is 2C. Although this protein is an indis-
pensable component of the replication complex, its exact role
in viral replication has remained elusive. Protein 2C appears to
be multifunctional, and this entails multiple interactions (23).
The amino acid sequence of 2C contains three conserved mo-
tifs which are typically found in NTP-binding proteins (motifs
A and B) or in members of helicase superfamily III (motif C)
(28–31, 69). In fact, ATPase activity has been demonstrated for
several picornavirus 2C proteins (37, 57, 60) whereas so far,
every attempt to demonstrate in vitro RNA helicase activity
has failed. Protein 2C contains two regions involved in RNA
binding (58). It has been suggested that, in poliovirus, this
binding occurs at the 3 cloverleaf of ()RNA (3–5); for echo-
virus, RNA binding was reported to occur in a nonspecific way
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(38). The amino-terminal region of the protein was predicted
to form an amphipathic helix (48), providing the major deter-
minant for its membrane-binding properties, although the C-
terminal portion of 2C was also found to interact with mem-
branes (21, 22, 64). The intracellular membranes, on which
replication complexes are localized, undergo extensive rear-
rangements upon viral infection, and it has been shown that
these structural changes are also in part ascribed to the pres-
ence of 2C/2BC (1, 11–13, 16, 63, 64). Furthermore, protein 2C
has been shown to contain a zinc-binding cysteine-rich motif
involved in RNA replication (50), to possess properties in-
volved in regulating the activity of the poliovirus 3C protease
(6), and to be implicated in the process of uncoating (41). A
study using the poliovirus inhibitor hydantoin [5-(3,4-dichloro-
phenyl)methylhydantoin] suggested a role for 2C during en-
capsidation (67), although the findings on which this conclu-
sion was based were disputed in a later study (68).
There is no approved antiviral therapy for the treatment of
picornavirus infections (59). Several molecules have previously
been reported to inhibit picornavirus replication, some of
which have entered clinical trials (20). As protein 2C is highly
conserved among picornaviruses and as its presence is indis-
pensable for efficient viral replication, this protein is an attrac-
tive target for viral inhibition. Presumably the best-studied
picornavirus inhibitor targeting the 2C protein so far is guani-
dine hydrochloride (GuaHCl) (14) (Fig. 1). Early studies with
this compound revealed that resistance to and/or dependence
on guanidine maps to the 2C region of poliovirus (2, 52–54).
Guanidine was shown to inhibit a 2C function that is required
for the initiation of ()RNA but not ()RNA synthesis or
RNA elongation (7). Bienz and coworkers showed that guani-
dine prevents the association of 2BC with host membrane
structures during viral replication (13). Moreover, it was shown
that guanidine at millimolar concentrations inhibits ATP hy-
drolysis (51), although other studies were not able to confirm
this observation (39, 57). Another compound that has been
known for decades and that selectively blocks enterovirus rep-
lication is 2-(alpha-hydroxybenzyl)-benzimidazole (HBB) (24–
27) (Fig. 1). Resistance to (or dependence on) HBB of echo-
virus is caused by single amino acid mutations in protein 2C
(32, 39). Also, compound 1-(4-fluorophenyl)-2-[(4-imino-1,4-
dihydropyridin-1-yl)methyl]benzimidazole hydrochloride (MRL-
1237) (Fig. 1) was shown to inhibit the replication of several
enteroviruses, and MRL-1237-resistant poliovirus mutants
were shown to carry a mutation in the 2C gene (61). Finally,
poliovirus mutants resistant to hydantoin (Fig. 1), which blocks
postsynthetic cleavages and assembly of poliovirus, were shown
to carry mutations scattered throughout the 2C sequence (67,
68), and hence this compound also appears to target entero-
virus protein 2C.
In the present study, we characterized the antiviral activity
of TBZE-029 {1-(2,6-difluorophenyl)-6-trifluoromethyl-1H,3H-
thiazolo[3,4-a]benzimidazole} (Fig. 1), a compound that we
recently described as an inhibitor of the replication of several
enteroviruses (19), and identified protein 2C as its molecular
target.
MATERIALS AND METHODS
Cells and viruses. Vero cells (ATTC CCL-81) or Buffalo green monkey
(BGM) cells were grown in minimal essential medium (Gibco, Merelbeke, Bel-
gium) supplemented with 10% heat-inactivated fetal bovine serum (Integro,
Leuvenheim, The Netherlands), 5% bicarbonate (Gibco, Merelbeke, Belgium),
and 5% L-glutamine (Gibco, Merelbeke, Belgium). Cells were grown at 37°C in
a 5% CO2 incubator. Coxsackievirus B3 was derived from plasmid p53CB3/T7,
which contains a full-length cDNA of CVB3 strain Nancy behind a T7 RNA
promoter (70). For assays involving virus growth, 2% fetal bovine serum was used
instead of 10%.
Compounds. TBZE-029 was synthesized as previously described (15). Envi-
roxime and MRL-1237 were synthesized by G. Pu¨rstinger (Institut fu¨r
Pharmazie, Universita¨t Innsbruck, Austria). GuaHCl was purchased from Sigma,
and HBB was from ChemPacific (Baltimore, MD). Rupintrivir was a kind gift
from Amy Patick (Pfizer, La Jolla, CA). All compounds were solubilized in
dimethyl sulfoxide (DMSO) and stored at 4°C. For working solutions, the DMSO
stocks were diluted in minimal essential medium to the desired concentration.
In vitro RNA transcription and transfection. Prior to in vitro RNA transcrip-
tion, plasmid p53CB3/T7 was linearized with SalI (Promega, Leiden, The Neth-
erlands). The digest was purified (gel and PCR purification kit; Promega, Leiden,
The Netherlands), and 2.5 g of DNA was used for in vitro RNA transcription
(Ribomax large-scale RNA production system; Promega, Leiden, The Nether-
lands). The transcription reaction was carried out at 37°C for 4 h, after which the
reaction mixture was DNase treated and the RNA was purified (RNA cleanup
system; Qiagen, Venlo, The Netherlands). Transfections were carried out in
25-cm2 culture flasks on Vero cells, grown to 75% confluence. Reaction mix-
tures, containing 2 ml OptiMEM (Gibco, Merelbeke, Belgium), 2.5 g of puri-
fied RNA, and 10 l of DMRIE-C transfection reagent (Invitrogen, Merelbeke,
Belgium) were incubated for 4 h at 37°C. Subsequently, the medium was replaced
with fresh growth medium and incubation was continued until the cultures
exhibited extensive cytopathic effect (CPE). At this point, flasks were subjected
to three rounds of freezing and thawing, and the collected supernatant was
titrated for infectious-virus content as described earlier (19).
Multicycle CPE reduction assays. The antiviral activity of the selected com-
pounds was initially determined using an MTS [3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium]-based CPE reduc-
tion assay. Briefly, cells grown to confluence in 96-well plates were infected with
100 50% cell culture infective doses (CCID50) of virus. After an adsorption
period of 2 hours at 37°C, virus was removed and serial dilutions of the com-
pounds were added. The cultures were further incubated at 37°C for 3 days, until
complete CPE was observed in the infected and untreated virus control (VC).
After removal of the medium, 90 l culture medium and 10 l MTS-phenazine
methosulfate (Promega, Leiden, The Netherlands) were added to each well.
After an incubation period of 2 h at 37°C the optical density (OD) of each well
was read at 498 nm in a microplate reader. CPE values were calculated as
follows: %CPE  100  (ODCC  ODCVB3Compound)/(ODCC  ODVC). In this
formula, ODCC corresponds to the OD of the uninfected and untreated cell
cultures, ODVC represents the OD of the infected and untreated cell cultures,
and ODCVB3Compound represents the OD of the CVB3-infected cell cultures
treated with a given concentration of compound. The 50% effective concentra-
tion (EC50) was defined as the concentration of compound that offered 50%
protection against virus-induced CPE and was calculated using logarithmic in-
terpolation.
FIG. 1. Structural formulae of TBZE-029 and earlier reported en-
terovirus inhibitors targeting protein 2C.
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Effect on viral RNA and infectious-virus yield in multicycle growth assays.
Vero cells, grown to confluence in 48-well plates, were infected with 100 CCID50
of virus. After an adsorption period of 2 hours at 37°C, virus was removed and
serial dilutions of the compounds were added. The cultures were further incu-
bated at 37°C for 3 days, until complete CPE was observed in the VC. At this
point, viral RNA was isolated from the supernatant using a viral RNA isolation
kit (Macherey-Nagel, Du¨ren, Germany) and quantified using real-time reverse
transcription-quantitative PCR (RT-qPCR). Quantification of infectious-virus
yields was done by end point titration. Serial 10-fold dilutions were tested in six
replicative wells of 96-well plates. Virus titers were calculated and expressed as
CCID50 values (55).
Analysis of viral RNA accumulation with subgenomic replicon pCB3/T7-Luc.
Accumulation of viral ()RNA was monitored by transfecting cells (in the
presence or absence of TBZE-029) with RNA derived from the SalI-linearized
plasmid p53CB3/T7-Luc, which contains a subgenomic CVB3 replicon carrying a
luciferase gene in place of the capsid-coding P1 region. At 2 h, 4 h, 6 h, and 8 h
posttransfection, the cells were washed three times with phosphate-buffered
saline (PBS) and lysed in 100 l of lysis buffer, and the luciferase activity was
measured in a liquid scintillation counter with the luciferase assay system ac-
cording to the recommendations of the manufacturer (Promega, Leiden, The
Netherlands). Luciferase activity was expressed in (relative) light units.
Quantitative analysis of CVB3 RNA by real-time RT-qPCR assays. Real-time
qPCR was performed on the ABI Prism 7000 sequence detection system (Ap-
plied Biosystems, Foster City, CA). Primers and probes were developed with
Primer Express software (Applied Biosystems) as described elsewhere (46). The
following primers and probe were used: a forward primer specific for nucleotides
2937 to 2957 (5-ACG AAT CCC AGT GTG TTT TGG-3), a reverse primer
specific for nucleotides 3003 to 2982 (5-TGC TCA AAA ACG GTA TGG ACA
T-3), and a TaqMan probe specific for nucleotides 2960 to 2977 (5-6-carboxy-
fluorescein-CGA GGG AAA CGC CCC GCC-6-carboxytetramethylrhodamine-
3). Each reaction was performed in 25 l of a PCR reagent mixture (One-Step
RT-qPCR mixture; Eurogentec, Seraing, Belgium) containing 900 nM of each
primer and 200 nM of the specific TaqMan probe. The PCR consisted of a
reverse transcription step (30 min at 48°C), a Taq activation step (10 min at
95°C), and 50 cycles of denaturation (15 s at 94°C) and annealing (1 min at 60°C).
The RNA copy number in each sample was determined by a standard curve
generated by increasing the copy number of a synthetic transcript corresponding
to 67 nucleotides of the CVB3 genome.
Time of drug addition studies. Vero cells, grown to confluence in 24-well
culture plates, were infected with 1  104 CCID50 of coxsackievirus B3. After an
adsorption period of 1 h at 37°C, virus was removed and replaced with 500 l
growth medium. At 1-hour intervals, 500 l of medium containing a 2 com-
pound solution was added (final concentration, 80 M). At 8 hours postinfection
(p.i.), the supernatant of the infected cultures was collected and viral RNA was
quantified using real-time RT-qPCR.
Analysis of viral polyprotein processing in vivo. BGM cells, grown to conflu-
ence in 24-well plates, were infected with 2  107 CCID50 of coxsackievirus B3.
At 5 h 15 min p.i., the medium was replaced with 300 l methionine-free
medium. Thirty minutes later, the cultures were pulse-labeled in methionine-free
medium containing 1 l/well of [35S]Met in the absence or presence of TBZE-
029 (final concentration, 80 M) for 15 min. At 6 h p.i. (5 h 15 min plus 30 min
plus 15 min), cells were washed twice with PBS and lysed in cold lysis buffer
containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Nonidet
P-40, and 0.05% sodium dodecyl sulfate (SDS). Translation products were ana-
lyzed on a 10% polyacrylamide gel containing SDS. The gels were fixed in 30%
methanol–10% acetic acid, rinsed in DMSO, fluorographed with 20% 2,5-diphe-
nyloxazole in DMSO, dried, and exposed to Kodak XAR film.
Single-cycle growth curves. Confluent Vero cell monolayers in 24-well plates
were infected with virus at a multiplicity of infection (MOI) of 1 for 30 min at
37°C. The cells were washed three times with PBS, supplied with the medium (in
the presence or absence of TBZE-029), and further incubated. At 2 h, 4 h, 6 h,
and 8 h p.i., cells were disrupted by three cycles of freezing and thawing. Virus
titers were determined by end point titration.
Generation of TBZE-029-resistant virus. Drug-resistant virus was generated
by growing virus in the presence of increasing concentrations of TBZE-029 on
confluent Vero cultures in 48-well culture plates. After 4 to 5 days, culture
supernatant was collected from those cultures that exhibited full CPE in the
presence of the highest concentration of compound. This virus was used for a
successive round of infection, a procedure that was repeated until full CPE was
noticed at concentrations of TBZE-029 that did not allow replication of wild-type
virus. Subsequently, the resistant-virus pool was subjected to two rounds of
plaque purification (in the presence of compound), and individual clones were
used for sequencing.
Site-directed mutagenesis. Seven mutant CVB3 clones, containing either sin-
gle or multiple amino acid replacements at positions 224, 227, and/or 229 in
protein 2C, were constructed. The seven clones were designated CVB3[A224V],
CVB3[I227V], CVB3[A229V], CVB3[A224V-I227V], CVB3[A224V-A229V], CVB3[I227V-A229V],
and CVB3[A224V-I227V-A229V]. The corresponding synthetic oligonucleotides (and
their complementary reverse oligonucleotides) were used for site-directed mu-
tagenesis: 5-GTC TTG GCA TCG ACC AAT GTA GGA TCT ATT AAT GCT
CCA ACC G-3, 5-GTC TTG GCA TCG ACC AAT GCA GGA TCT GTT
AAT GCT CCA ACC G-3, 5-GTC TTG GCA TCG ACC AAT GCA GGA
TCT ATT AAT GTT CCA ACC G-3, 5-GTC TTG GCA TCG ACC AAT
GTA GGA TCT GTT AAT GCT CCA ACC G-3, 5-GTC TTG GCA TCG
ACC AAT GTA GGA TCT ATT AAT GTT CCA ACC G-3, 5-GTC TTG
GCA TCG ACC AAT GCA GGA TCT GTT AAT GTT CCA ACC G-3, and
5-GTC TTG GCA TCG ACC AAT GTA GGA TCT GTT AAT GTT CCA
ACC G-3. The mutated sequences are underlined. Site-directed mutagenesis
was performed with plasmid p53CB3/T7 using the XL Blue large site-directed
mutagenesis kit (Stratagene, Amsterdam, The Netherlands), according to the
manufacturer’s instructions. After mutagenesis, the individual clones were veri-
fied by sequencing. Next, a 711-bp fragment containing the desired mutations
was isolated using the enzymes BssHII and XbaI and reintroduced into an
original, nonmutagenized clone of the same plasmid, p53CB3/T7. From these
mutants, RNA transcripts and infectious viruses were generated as described
above.
Sequencing. PCR fragments that cover the entire CVB3 genome were gener-
ated and analyzed using the cycle sequencing method (ABI Prism Big Dye
Terminator cycle sequencing ready reaction kit). Both DNA strands were se-
quenced. Sequencing data were obtained using an ABI 373 automated sequence
analyzer (Applied Biosystems, Lennik, Belgium), and sequences were analyzed
using the Vector NTI software (Invitrogen, Merelbeke, Belgium).
Cloning and expression of wild-type and an active-site mutant coxsackievirus
B3 protein 2C. The cDNA encoding the 2C domain of CVB3 was amplified by
PCR with the following primers: forward primer, GGGGACAAGTTTGTACA
AAAAAGCAGGCTTAGAAAACCTGTACTTCCAGGGTaacaatagctggcttaag
aaatttac (the recombination site is in uppercase letters; the tobacco etch virus
protease cleavage site is underlined and uppercase and is followed by the gene-
specific sequence [lowercase]); reverse primer, GGGGACCACTTTGTACAAG
AAAGCTGGGTCTTATTActggaacagtgcctcaagcg (the recombination site is in
uppercase letters; stop codons [underlined, uppercase] are followed by the gene-
specific sequence [lowercase]). The resulting PCR product was cloned via the
Gateway system (Invitrogen, Merelbeke, Belgium) into the compatible
pDEST17 expression vector in order to fuse the gene of interest with N-terminal
ATGs (His6, His6-maltose binding protein, His6-glutathione S-transferase
[GST], His6-Trx). A soluble-expression screening was performed for each fusion
in order to define the best fusion expressed in its best condition (10). The
His6-GST-2C was chosen and expressed solubly in Rosetta pLysS, at 20°C in 16
g/liter tryptone–10 g/liter yeast extract–5 g/liter NaCl containing 100 g/ml am-
picillin (2 YT)-ampicillin-chloramphenicol medium. Similarly, an active-site mu-
tant of 2C which carried the K135A mutation in NTPase motif A was cloned and
expressed. This mutation was introduced using site-directed mutagenesis on the
CVB3 full-length clone pCB53/T7 as described earlier using the following syn-
thetic oligonucleotide (and its complementary reverse oligonucleotide): 5-AGC
CCT GGT GCC GGC GCG TCG GTG GCA ACA AAC TT-3, where the
mutated sequence is underlined.
Production and purification of protein 2C of coxsackievirus B3. A volume of
60 ml of an overnight preculture was used to inoculate 2 liters of 2YT medium
supplemented with ampicillin and chloramphenicol. The culture was grown at
37°C until the OD at 600 nm reached 0.5. Induction was then performed over-
night with 500 M IPTG (isopropyl--D-thiogalactopyranoside) at 20°C. The
culture was stopped by centrifuging for 10 min at 6,000  g. The pellet was
resuspended in lysis buffer (50 mM Tris, 300 mM NaCl, 10 mM imidazole [pH 8],
0.1% Triton X-100, 5% glycerol, 0.25 mg/ml lysozyme, EDTA-free antiprotease
cocktail [Roche, Brussels, Belgium]) before being stored at 80°C. Cells were
lysed by sonication. The lysate was clarified by centrifugation at 16,000  g for 30
min. The purification consisted of two steps. First immobilized-metal affinity
chromatography was performed on a 5-ml Hisprep column using the Akta
Xpress (GE Healthcare, Diegem, Belgium) system. After a washing step at 50
mM imidazole, the protein was eluted in 50 mM Tris, 300 mM NaCl, and 250
mM imidazole, pH 8. Both GST alone and the GST-2C fusion were copurified.
The two proteins were separated by gel filtration using a HiLoad 16/60 Super-
dex200 equilibrated in 10 mM Tris, 300 mM NaCl, and 2 mM dithiothreitol, pH
7.5. Purity was checked on an acrylamide SDS-polyacrylamide gel electrophore-
sis gel colored with Coomassie blue. The pool corresponding to the GST-2C
fusion (first peak) was concentrated using an Amicon Ultra centrifugal filter unit
4722 DE PALMA ET AL. J. VIROL.
 o
n
 July 11, 2012 by Universiteitsbibliotheek
http://jvi.asm.org/
D
ow
nloaded from
 
(30,000-Da cutoff; Millipore, Brussels, Belgium) over 1 mg/ml and diluted in 50%
glycerol for storage at 20°C. For the K135A mutant, an additional affinity
purification was performed on glutathione-Sepharose 4B (GE Healthcare) fol-
lowing the gel filtration step. The purification was carried out in the gel filtration
buffer, and elution was in the buffer supplemented with 10 mM reduced gluta-
thione. The remaining reduced glutathione was then removed by subsequent
washes during the protein concentration.
ATPase assay and detection. ATPase reactions with 20-l mixtures were
performed in buffer O (Fermentas, St Leon-Rot, Germany), containing purified
CVB3 protein 2CATPase-GST and 10 M [	-32P]ATP (10 Ci/l; Hartmann
Analytic, Braunschweig, Germany), either in the presence or absence of antiviral
compounds. Reactions were performed at 30°C or 37°C and stopped by addition
of 80 l 0.1 M EDTA. One microliter of the reaction mixture was applied to
polyethyleneimine cellulose-coated thin-layer chromatography plates (Merck,
Overijse, Belgium) and run for 2 h in thin-layer chromatography buffer (0.15 M
LiCl, 0.15 M formic acid). The chromatogram was exposed to Biomax MR X-ray
film (Kodak, Brussels, Belgium) and analyzed.
RESULTS
TBZE-029 inhibits viral replication in a dose-dependent
manner. From a series of 2,6-dihalophenyl-substituted 1H,3H-
thiazolo[3,4-a]benzimidazoles with antienterovirus activity,
TBZE-029 (designated compound 4a in reference 19) was se-
lected for mechanistic studies. As recently reported, TBZE-
029 inhibits virus-induced CPE formation of several enterovi-
ruses in multicycle-growth assays (19). To verify that the
protection against CPE formation was indeed due to inhibition
of viral replication, CVB3 RNA from culture supernatant was
quantified by means of real-time RT-qPCR. No viral RNA was
detectable in the supernatant of infected cultures that had
been treated with TBZE-029 at concentrations of 33 M or
higher (Fig. 2A); at a concentration of 3.3 M, still a 40%
reduction in viral RNA was observed compared to the un-
treated control. These data were corroborated by determining
the effect of the compound on infectious-virus yield. The de-
crease in viral RNA yield was paralleled by a decrease in
infectious-virus yield (Fig. 2B).
TBZE-029 exerts its antiviral activity at a stage that coin-
cides with viral RNA synthesis and polyprotein processing/
synthesis. To define the stage in the viral replication cycle at
which TBZE-029 exerts its antiviral activity, time of drug ad-
dition studies were performed. A fixed concentration of
TBZE-029 (80 M) was added at 1-hour intervals, starting at
1 hour preinfection. As shown in Fig. 3, a complete inhibition
of viral replication was observed at the end of a single repli-
cation cycle (8 h) when TBZE-029 was added within the first 3
hours after infection. When the compound was added at a time
point later than 3 h p.i., a gradual loss in antiviral activity was
noticed, indicating that TBZE-029 does not hamper early (at-
tachment, entry, or uncoating) or late (assembly or release)
events. In parallel, we monitored the single-cycle kinetics of
intracellular viral RNA synthesis by means of RT-qPCR (Fig.
3A and B). From panel A it is evident that viral RNA is first
detected intracellularly after 3 h p.i., and panel B reveals that
a very sudden, steep increase in intracellular viral RNA levels
occurs between 4 and 7 h p.i. This increase in viral RNA levels
reaches a plateau at 7 to 8 h p.i. The gradual/steep loss of
TBZE-029 activity coincides with the time points where a grad-
ual/steep increase in intracellular viral RNA is detected.
TBZE-029 inhibits accumulation of viral positive-strand
RNA. To study the effect of TBZE-029 on viral positive-strand
RNA accumulation, we used a chimeric subgenomic replicon
(pCB53/T7-Luc) in which the P1 region of pCB53/T7 is re-
placed by the firefly luciferase gene (70). It was previously
shown that the activity of the reporter protein following trans-
fection correlates with the levels of RNA that accumulate
intracellularly (70). The presence of TBZE-029 at a concen-
tration of 80 M almost completely inhibited accumulation of
viral positive-strand RNA, whereas a 50-fold increase in lu-
ciferase activity was detected in the absence of the drug (Fig.
4). GuaHCl (2 mM) was included as a control and also com-
pletely inhibited viral RNA accumulation.
TBZE-029 does not affect polyprotein processing. As shown
using the CVB3-luc replicon, TBZE-029 inhibits accumulation
of viral ()RNA. Theoretically, this could be due to adverse
effects of the drug on viral protein synthesis or polyprotein
processing. To exclude this possibility, the effect of TBZE-029
on in vivo polyprotein synthesis and/or processing was moni-
tored. At 5 h 45 min p.i., infected-cell cultures were pulse-
labeled for 15 min with [35S]Met in the presence (80 M) or
absence of the compound after starvation for methionine for
30 min. From Fig. 5 it is evident that the viral polyprotein
processing pattern remains unaffected in the presence of
TBZE-029. This excludes the possibility that the deleterious
effects of TBZE-029 on viral ()RNA accumulation are due to
an altered rate of protein translation or a general defect in
polyprotein processing.
FIG. 2. Dose-dependent inhibition of viral replication by TBZE-
029. Vero cells grown to confluence in 48-well plates were infected
with CVB3, treated with different concentrations of TBZE-029, and
incubated for 3 days at 37°C until extensive CPE was noticed. At that
point, supernatant was collected and assayed for the presence of viral
RNA (by means of real-time RT-qPCR) (A) or infectious-virus yield
(by end point titration) (B).
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Resistance to TBZE-029 maps to a short sequence flanking
domain C in nonstructural protein 2C. To identify the precise
viral target of TBZE-029, drug-resistant CVB3 was generated.
Initially, we tried to recover resistant clones following agar
(containing TBZE-029) overlay of infected-cell cultures, but
this resulted in complete inhibition of plaque formation and
hence, in this particular case, appeared to be not an ideal
method to isolate resistant virus. Therefore, we grew virus in
liquid medium, in the presence of increasing concentrations of
compound, starting at 0.5 EC50. To prevent the generation of
resistant clones deriving from one common predecessor, three
independent serial passages were carried out. After 15 pas-
sages, three highly resistant virus pools that replicated effec-
tively in the presence of 330 M TBZE-029 were obtained.
These virus pools were subjected to two rounds of plaque
purification in the presence of TBZE-029, after which six single
clones were picked and sequenced. Each of these clones car-
ried three amino acid substitutions (A224V, I227V, and
A229V) in protein 2C, immediately downstream of the con-
served NTPase domain C, except for clone 5, which carried
mutation A224L instead of A224V (Table 1). Clones 2 and 6
carried an additional mutation, K107R in protein 2C and
S229T in protein 3D, respectively. Since mutations 2C K107R
and 3D S299T each occurred only once in different clones, they
were not further considered. To characterize the actual con-
tribution of the A224V, I227V, and A229V mutations to the
drug resistance phenotype, seven recombinant viruses were
generated, containing either one, two, or three mutations (Ta-
ble 2). To this end, site-directed mutagenesis was performed
with plasmid p53CB3/T7 and RNA transcripts were trans-
fected into Vero cells. Two to 3 days p.i., all cultures exhibited
full CPE, except for those infected by clones 3 (A229V) and 5
(A224V and A229V). Since for other 2C inhibitors, drug-de-
pendent phenotypes that could be rescued by addition of
GuaHCl have been described previously (32, 66), constructs 3
FIG. 3. Time of drug addition. TBZE-029 (80 M) was added to CVB3-infected cell cultures at 1-hour intervals, starting at 1 h before infection.
At 8 h p.i., intra- and extracellular viral RNA was collected and quantified by means of real-time RT-qPCR. (Insets A and B) Kinetics of a single
viral replication cycle of CVB3 in the absence of drug (intracellular viral RNA monitored by RT-qPCR).
FIG. 4. Analysis of viral RNA accumulation with subgenomic rep-
licon pCB3/T7-Luc. Accumulation of viral ()RNA was monitored by
transfecting BGM cells grown to confluence (in the presence or ab-
sence of TBZE-029) with RNA derived from a chimeric subgenomic
replicon (pCB53/T7-Luc). In this replicon, the P1 region of pCB53/T7
is replaced by the firefly luciferase gene. At the indicated times post-
transfection, the luciferase activity was quantified and expressed in
(relative) light units (RLU).
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and 5 were transfected in the presence of 400 M GuaHCl.
Remarkably, 3 to 4 days p.i. full CPE was noted in both cul-
tures. When cultures exhibited extensive CPE, culture flasks
were freeze-thawed three times, supernatant was collected,
and infectious virus was quantified by titration. The mutant
viruses were designated clones 1 to 7 (Table 2), and three of
these (clones 4, 6, and 7) were sequenced to verify that no
other mutations accumulated after transfection. Subse-
quently, each clone was evaluated for its susceptibility to
TBZE-029. Introduction of the two single mutations at po-
sitions 224 and 227 (clones 1 and 2) proved not sufficient to
confer the TBZE-029 resistance phenotype. When these
mutations were combined, however, a high-TBZE-029-resis-
tance phenotype (clone 4) was generated. Unlike single
mutations at positions 224 and 227, a single mutation at
position 229 (clone 3) resulted in a transcript that was in-
fectious only in the presence of GuaHCl. This dependence
phenotype was also observed when an additional mutation
at position 224 was introduced (clone 5). Surprisingly, the
dependence phenotype was “rescued” when the 229 muta-
tion was combined with the mutation at position 227, lead-
ing to a resistant, but nondependent virus (clone 6). The
combination of the three mutations resulted, as expected, in
a high-resistance phenotype (clone 7).
TBZE-029-resistant virus exhibits cross-resistance with
other 2C inhibitors. Next, the susceptibilities of the various
mutants to inhibition by other 2C inhibitors (GuaHCl, MRL-
1237, and HBB) were studied. Hydantoin was not included,
since it lacked antiviral activity against wild-type CVB3 (data
not shown). For HBB, a pattern of resistance comparable to
that for TBZE-029 was observed. This pattern was almost
identical to that for MRL-1237, except in the case of clone 2
(carrying a single mutation at position 227), which was suscep-
tible to inhibition by TBZE-029 and HBB but highly resistant
to MRL-1237. Also for GuaHCl, the observed antiviral sensi-
tivity phenotypes were similar to those for TBZE-029, with the
exception of that of clone 1, carrying a single amino acid
mutation at position 224. This clone was sensitive to inhibition
by TBZE-029, MRL-1237, and HBB but proved highly resis-
tant to GuaHCl. Two compounds with a target that is different
from 2C were included as well: enviroxime (targeting protein
3A) and the 3C-protease inhibitor rupintrivir. As expected,
none of the constructed mutants had a reduced sensitivity to
these two reference compounds.
Phenotypic characterization of mutant 6 (I227V, A229V).
Clone 6, carrying the two most important mutations for resis-
tance (I227V and A229V), was selected for further character-
ization of a single growth cycle. Both mutant and wild-type
viruses were used for infection at an MOI of 1, and growth
kinetics were defined by end point titration. At 8 h p.i., recom-
binant mutant 6 yielded virus titers that were 2 logs lower
than those of wild-type CVB3, which indicates that the muta-
tions at positions 227 and 229 in protein 2C reduce viral fitness
(Fig. 6A and B). As expected, mutant 6 produced markedly
smaller plaques than wild-type CVB3 (Fig. 6C), which reflects
slower growth kinetics in multiple cycles. As expected, only
mutant 6 could replicate to normal titers in the presence of
TBZE-029 (80 M), whereas 10 M of enviroxime inhibited
both mutant and wild-type virus (Fig. 6A and B). Inspection of
the plaque phenotypes produced by the other recombinant
viruses showed that only mutant 5 was able to produce plaques
similar to those produced by wild-type virus, whereas the other
viruses generated plaques that had a small or intermediate size
compared to those of wild-type virus (Fig. 6C).
The ATPase activity of 2C is not inhibited by TBZE-029. A
GST-CVB3 protein 2C fusion was expressed and purified. A
concentration- and time-dependent ATPase activity for pro-
tein 2C was demonstrated (Fig. 7A and B). Based on these
data, protein 2C was used at 3 M for 30 min at 37°C in
subsequent experiments. To verify the specificity of the enzyme
activity, an active-site mutant of 2C (K135A) was expressed
and purified. It was reported earlier that mutation of the first
FIG. 5. Effect of TBZE-029 on polyprotein processing. At 5 h 45
min p.i., BGM cells grown to confluence in 24-well plates were pulse-
labeled for 15 min with [35S]Met after starvation in methionine-free
medium for 30 min, either in the presence (80 M) or absence of
TBZE-029. Cells were lysed, and translation products were analyzed
by SDS-polyacrylamide gel electrophoresis.
TABLE 1. Amino acid mutations identified in six CVB3 clones
following selection for TBZE-029-resistant variants
CVB3
protein
Amino acid
substitution
Nucleotide
Clone(s)
Substitution Position
2C K107R AAG3AGG 3620 2
2C A224V/L GCA3GTA/TTA 3971/3970 1, 2, 3, 4, 6/5
2C I227V ATT3GTT 3979 1, 2, 3, 4, 5, 6
2C A229V GCT3GTT 3986 1, 2, 3, 4, 5, 6
3D S299T TCA3ACA 6064 6
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conserved lysine residue in NTPase motif A (GXXXXGKS)
dramatically reduces or abolishes ATPase activity (60, 65),
which we could confirm for CVB3 protein 2C (Fig. 7C and D).
We next wanted to study whether the antiviral activity of
TBZE-029 was due to inhibition of the ATPase activity of 2C.
However, even at a concentration as high as 100 M of TBZE-
029, no inhibitory effect on the ATPase activity was noted (Fig.
7C). Likewise, none of the other 2C inhibitors, including
GuaHCl (2 mM), were able to inhibit the ATPase activity
of 2C.
FIG. 6. Phenotypic characterization of wild-type CVB3 and TBZE-029-resistant mutant 6 (I227V, A229V). Confluent Vero monolayers in
24-well plates were infected with wild-type (WT) (A) or mutant (B) virus at an MOI of 1 for 30 min at 37°C. The cells were washed and further
cultured in the presence or absence of TBZE-029. At the indicated times postinfection, cells were disrupted by three cycles of freezing and thawing
and viral titers were determined by end point titration. (C) Plaque phenotypes of wild-type CVB3 and recombinant clones.
TABLE 2. Resistance pattern of recombinant CVB3 carrying 2C mutations A224V, I227V, and A229V and cross-resistance pattern with
other antienterovirus compoundsa
Clone
2C mutationb Mean EC50 (M) of indicated antiviral molecule 
 SDc
A224V I227V A229V
2C inhibitors Non-2C inhibitors
TBZE-029 HBB MRL-1237 Guanidine Enviroxime Ruprintrivir
WTd 7.2 
 3.1 55 
 2 15 
 6 272 
 5 0.18 
 0.03 4.7 
 1.0
1 X 9.3 
 0.9 56 
 4 12 
 2 1,681  15 0.18 
 0.03 4.4 
 0.5
2 X 10 
 0 59 
 3 199  27 286 
 19 0.22 
 0.02 4.3 
 0.4
3 X Dep Dep Dep Dep
4 X X >330 283  18 >314 1,687  60 0.17 
 0.05 4.4 
 0.4
5 X X Dep Dep Dep Dep
6 X X 210  72 270 23 >314 1,657  60 0.14 
 0.01 4.3 
 0.6
7 X X X >330 >446 >314 >10,468 0.20 
 0.01 2.4 
 1.5
Res poole >330 >446 202 12 >10,468 0.47 
 0.17 4.3 
 0.9
a Mutations at residues 224, 227, and 229 in protein 2C were introduced, either alone or combined, in a full-length cDNA of CVB3. In vitro transcription, followed
by transfection, led to seven recombinant viruses that were evaluated for their susceptibility to TBZE-029 and reference compounds.
b X indicates the presence of the mutation.
c Data were determined by inhibition of CPE formation. Dep, clones that were dependent on GuaHCl in order to generate infectious virus upon transfection. Data
are from at least three independent experiments. Boldface indicates resistance to the tested drug.
d WT, wild type.
e Res pool, resistant pool of CVB3, obtained after serial passaging in the presence of TBZE-029 and prior to plaque purification.
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DISCUSSION
Protein 2C is among the most conserved proteins in the
picornavirus family. This protein contains three conserved mo-
tifs that are characteristic of superfamily III (SFIII) of the
NTPase/helicase proteins (30). Motif A (GXXXXGKS) is
most likely involved in the binding of the phosphate moieties
of the NTP substrate, whereas motif B (two Asp residues
preceded by a -strand) may fix the Mg2 involved in the
cleavage of the NTP -phosphate (66). Domain C consists of
an Asn preceded by a run of hydrophobic residues. To date, no
helicase activity could be demonstrated for picornavirus 2C
(57). Helicases are molecular motors that use the energy of
ATP hydrolysis to unidirectionally translocate along nucleic
acids and separate (unwind) the complementary strands of the
nucleic acid duplex (34). In recent years, important progress in
determining the structure and function of SFIII helicases has
been made (35, 40, 44). In vitro ATPase activity was demon-
strated for the purified 2C proteins of poliovirus (45, 57),
echovirus (37), human parechovirus (60), and coxsackievirus
B3 (this study). Studies have revealed the presence of, apart
from 2C’s NTPase domain, an N-terminal amphipathic helix
(48), a membrane-binding region (22), two RNA-binding do-
mains (58), and a zinc-binding cysteine-rich motif (50). More-
over, 2C was shown to be involved in a multitude of processes
required for viral replication, including virus uncoating (41),
host cell membrane binding and rearrangement (16, 63, 64),
formation of the viral cytoplasmic replication vesicles (1, 16,
22, 62–64), RNA binding and RNA synthesis (4, 5, 7, 71), and
possibly encapsidation (67, 68).
Here we describe the antiviral activity of the thiazoloben-
zimidazole TBZE-029, which we recently reported as an inhib-
itor of enterovirus replication (19). TBZE-029 inhibited the
release of infectious virus progeny in a dose-dependent man-
ner. It blocked viral RNA synthesis without affecting viral
polyprotein processing. These findings are corroborated by
time of drug addition studies, indicating that TBZE-029 exerts
its activity at a stage that coincides with the replication of viral
RNA.
To identify the precise target of TBZE-029, drug-resistant
CVB3 was generated. Genotyping of this virus led to the iden-
tification of three amino acid mutations at positions 224, 227,
and 229 in protein 2C that were present in all clones. These
residues are located in a region which is just downstream of
motif C and have been predicted to form a loop between a beta
strand and an alpha helix (64, 66). Reintroduction of these
mutations, either alone or combined, into a full-length clone of
CVB3 generated seven recombinant clones, which were fur-
ther characterized. Single amino acid mutations at positions
FIG. 7. ATPase activity of CVB3 protein 2C and effect of 2C-targeting compounds on enzyme activity. The ATPase activity of CVB3 GST-fused
protein 2C was detected using [	-32P]ATP as a substrate. The enzymatic activity was assessed in the presence of different concentrations of protein
2C (A) or as a function of time (B). (C) Generation of an active-site mutant of protein 2C. (D) ATPase activity was assessed in the presence of
TBZE-029 and other reported 2C inhibitors at 100 M (or 2 mM for GuaHCl).
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224 and 227 were not sufficient to confer resistance to TBZE-
029, but highly resistant virus was obtained when the amino
acid mutation at position 227 was combined with the mutations
at either position 224 or 229 or both. Moreover, two transcripts
(clones 3 [A229V] and 5 [A224V and A229V]) were dependent
on GuaHCl to become infectious upon transfection. Clone 6
(I227V and A229V) showed delayed single-cycle growth kinet-
ics and produced markedly smaller plaques than wild-type vi-
rus. In fact, only mutant 5 (exhibiting a GuaHCl dependence
phenotype) was able to produce plaques similar to those of
wild-type virus.
Interestingly, previous studies with the antiviral compound
HBB in echovirus 9 reported that altered sensitivity to this
drug mapped, similarly to our findings, to the Ile and Ala
residues at positions 227 and 229, respectively (32, 39). In
particular, the I227L mutation, either alone or combined with
the A229V mutation, conferred resistance to HBB. Akin to the
observations in the current study, a single mutation of Ala at
position 229, however, led to a noninfectious RNA transcript,
which could be rescued by the addition of HBB or GuaHCl
(32, 39). Studies of cross-resistance to HBB, using the recom-
binant TBZE-029-resistant coxsackievirus clones, showed an
identical pattern of resistance (Table 2). These observations
suggest that TBZE-029 and HBB probably have similar mech-
anisms of action.
Another benzimidazole derivative, MRL-1237, was also re-
cently reported to select for mutations in poliovirus 2C (61). Of
15 mutants, 14 were shown to carry a single amino acid muta-
tion at position 164, conferring high resistance to both MRL-
1237 and guanidine. The other mutant carried a mutation at
position 120 but exhibited only weak resistance to MRL-1237
and was not cross-resistant to guanidine. None of the muta-
tions described for MRL-1237 were observed in TBZE-029-
resistant coxsackievirus. However, when the constructed
coxsackievirus mutants in this study were evaluated for cross-
resistance to MRL-1237, a substantial overlap in the resistance
profile was noticed. In fact, all the constructed mutants, except
for the one carrying a single amino acid mutation at position
224, showed cross-resistance to MRL-1237 (Table 2). This
suggests that the antiviral activity of MRL-1237 is also depen-
dent on interactions within this short region in 2C (224-227-
229). However, the precise interactions between protein 2C
and MRL-1237 must differ from those between 2C and TBZE-
029 or HBB, since amino acid 227 has a greater impact on the
resistance profile of MRL-1237 than on those of TBZE-029
and HBB.
The most extensively studied inhibitor of 2C is probably
GuaHCl (14, 17, 42, 56). Several studies with guanidine-resis-
tant poliovirus (52–54, 66) led to the conclusion that guanidine
resistance can be attributed mainly to two mutations in a loop
adjacent to motif B, designated “class N” or “class M” muta-
tions. The first class involves a mutated Asn at position 179 and
the second class a mutated Met at residue 187. Besides these
“main” mutations, guanidine-resistant poliovirus was shown to
carry some additional mutations that were located at residue
143, 227, or 233. It should be emphasized that residue 227 is
also involved in the resistance of echovirus to HBB (39) and, as
reported here, of coxsackievirus to TBZE-029. Shimizu et al.
(61) demonstrated that poliovirus carrying either of the gua-
nidine “main” mutations was not only resistant to guanidine
but also cross-resistant to MRL-1237.
A general important observation is that almost every muta-
tion conferring resistance to any 2C inhibitor reported to date
implies almost by definition cross-resistance to GuaHCl, which
is not necessarily true the other way around. Similarly, the
drug-dependent RNA transcripts, observed when echo- and
coxsackievirus 2C proteins were mutated at position 229, be-
came infectious upon transfection only in the presence of
GuaHCl. An overview of all reported amino acid mutations
involved in resistance to 2C inhibitors reported in this study
and the literature to date is presented in Fig. 8. Even though
several compounds select for different amino acid mutations at
different sites, it is evident that most of the mutations are
clustered within each of the three NTPase/helicase domains.
In the present study, no inhibition of the in vitro ATPase
activity of purified 2C by TBZE-029 was observed. In fact,
studies with purified 2C in an in vitro system may not be a
valuable model for testing the inhibitory action of drugs, given
the complex interactions with membranes and other viral and
cellular proteins that have been described for 2C in infected
cells (64).
Alternatively, another 2C function may be inhibited. One
might speculate that, as the region just outside domain C is a
“hot spot” for mutations and as this domain is conserved
among the helicase SFIII, the putative helicase function is the
target of TBZE-029. Although this is a possible explanation, it
should be emphasized again that so far all attempts to dem-
onstrate that purified 2C exerts in vitro helicase activity have
failed (57). The CVB3 precursor protein 2BC has previously
been shown to homomultimerize (18). Importantly, TBZE-029
did not interfere with 2BC homomultimerization (our unpub-
lished data).
Several questions remain to be addressed. Is TBZE-029 an
FIG. 8. Overview of mutations identified in several enteroviruses
showing resistance to several 2C inhibitors. The bar represents the
329-amino-acid protein 2C. Dots represent reported amino acid mu-
tations present in virus resistant to 2C inhibitors. A, B, and C represent
the conserved NTPase/helicase domains.
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inhibitor of the enterovirus helicase? What is the molecular
interaction between the identified amino acids flanking domain
C and TBZE-029? What is the importance of residue 229 since
mutation of this residue generates noninfectious RNA tran-
scripts? Unraveling the precise mechanism of action by which
TBZE-029 inhibits picornavirus replication may (i) provide
insights into the biology of picornavirus replication and (ii)
allow the rational design of more-potent analogues as novel
inhibitors.
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